- Biotechnology company Destiny Pharma provided a positive update on its preparing for a phase 3 trial of its microbiome therapeutic NTCD-M3 aimed at preventing life threatening infections.

The phase 3 clinical study was progressing 'well', and remained on schedule to commence in 2022, the company said.

The company established a NTCD-M3 clinical advisory board consisting of Professor Dale Gerding MD US, who discovered NTCD-M3, Professor Mark Wilcox MD, UK key opinion leader in CDI and other medical and drug development experts with recent experience of running and designing international phase 3 clinical studies in CDI.

The company has also initiated the supplier selection of a clinical trial organisation for the phase 3 study.

Planning for the single phase 3 clinical study 'needs to be completed before submitting marketing authorisation applications in the US and Europe,' the company said.

At 9:56am: [LON:DEST] Destiny Pharma Plc share price was 0p at 68.5p

Story provided by